Ozempic and Vision Loss (NAION): The Emerging Legal Claims

An emerging and deeply concerning injury linked to GLP-1 receptor agonist drugs is non-arteritic anterior ischemic optic neuropathy (NAION) — a condition that causes sudden, painless vision loss that is often permanent. A 2024 study from Harvard Medical School published in JAMA Ophthalmology found that patients using semaglutide (the active ingredient in Ozempic and Wegovy) had a significantly elevated risk of developing NAION compared to non-users. This research has opened a new front in the GLP-1 litigation and raised urgent questions for the millions of patients taking these medications.

What Is NAION?

NAION occurs when blood flow to the optic nerve — the nerve that transmits visual information from the eye to the brain — is suddenly reduced or interrupted. This lack of blood flow damages the nerve fibers, resulting in vision loss that typically affects one eye at a time.

According to the National Eye Institute (NEI), key characteristics of NAION include:

• Sudden onset — patients typically notice vision loss upon waking, as NAION often occurs during sleep when blood pressure naturally drops
• Painless — unlike many eye conditions, NAION does not cause eye pain, which can lead patients to delay seeking treatment
• Visual field defects — the vision loss often affects the lower or upper half of the visual field in the affected eye, though patterns vary
• Permanent damage — while some patients experience partial recovery, many are left with permanent vision impairment in the affected eye
• Risk to the other eye — patients who develop NAION in one eye face an elevated risk (approximately 15-20%) of developing it in the other eye

NAION is the most common cause of sudden optic nerve-related vision loss in adults over 50, but the Harvard study’s findings suggest that GLP-1 drugs may be causing it in younger patients and at significantly higher rates than background population rates.

The Harvard Study: What the Research Shows

The study published in JAMA Ophthalmology was conducted by researchers at Massachusetts Eye and Ear, a Harvard Medical School affiliate. The key findings were striking:

• Patients prescribed semaglutide for type 2 diabetes had a significantly higher cumulative incidence of NAION compared to patients on non-GLP-1 diabetes medications
• Patients prescribed semaglutide for weight management also showed an elevated risk compared to patients using non-GLP-1 weight loss treatments
• The association persisted after adjusting for known NAION risk factors including diabetes itself, hypertension, and obstructive sleep apnea

The researchers noted that while the study was retrospective and further research is needed to establish causation definitively, the signal was strong enough to warrant concern and further investigation by the FDA and the medical community.

Why GLP-1 Drugs May Cause NAION

The exact mechanism by which GLP-1 receptor agonists may trigger NAION is still being studied, but several hypotheses have been proposed:

• Rapid weight loss — significant, rapid weight loss can alter cardiovascular dynamics and may affect blood flow to the optic nerve. GLP-1 drugs can cause substantial weight loss in a relatively short period.
• Blood pressure changes — GLP-1 drugs can lower blood pressure, and reduced perfusion pressure to the optic nerve during sleep may contribute to ischemic events.
• Direct vascular effects — GLP-1 receptors are present in vascular tissue, and the drugs may have direct effects on the small blood vessels supplying the optic nerve.
• Compounding risk factors — many patients taking GLP-1 drugs already have diabetes, hypertension, or other conditions that increase NAION risk, and the medication may push an already-vulnerable optic nerve past a tipping point.

The Legal Landscape

NAION claims represent a newer category within the broader GLP-1 litigation. While gastroparesis and bowel obstruction cases have been the primary focus of the MDL to date, NAION claims are gaining traction as the Harvard study’s findings receive wider attention and more patients come forward.

The core legal theory is the same as in other GLP-1 claims: the manufacturers knew or should have known about the risk of NAION and failed to adequately warn patients and prescribers. The Harvard study, combined with adverse event reports to the FDA’s FAERS database, suggests that signals about this risk were available and should have prompted earlier investigation and disclosure.

As of early 2026, NAION cases are being evaluated for inclusion in the MDL proceedings. The strength of these claims will depend on several factors:

• Temporal relationship — how closely the onset of NAION followed initiation of GLP-1 therapy
• Exclusion of other causes — whether the patient’s medical history includes other known NAION risk factors that could independently explain the event
• Ophthalmologic documentation — detailed records from an ophthalmologist or neuro-ophthalmologist documenting the NAION diagnosis, visual field testing, and optic nerve imaging

What to Do If You Are Affected

If you are taking or have taken a GLP-1 drug and experience sudden vision loss, take the following steps:

1. Seek immediate medical attention. Sudden vision loss is a medical emergency. Go to an emergency room or see an ophthalmologist urgently. Prompt evaluation is critical for documenting the event and ruling out other treatable causes.

2. Get a comprehensive eye exam. A neuro-ophthalmologist can perform the specialized testing needed to diagnose NAION, including visual field testing, optical coherence tomography (OCT), and fundoscopic examination.

3. Inform your doctors about your GLP-1 use. Make sure your ophthalmologist and primary care doctor know about your medication history. This information is important for both your medical care and any potential legal claim.

4. Preserve your medical records. Obtain copies of your ophthalmology records, prescription history, and any emergency room visits related to the vision loss.

5. Consult an attorney. An attorney experienced in GLP-1 litigation can evaluate whether your NAION diagnosis may give rise to a legal claim. Consultations are free and confidential.

Frequently Asked Questions

Is vision loss from NAION permanent?

In many cases, yes. While some patients experience partial improvement in the weeks to months after the event, most are left with some degree of permanent vision impairment. There is currently no proven treatment to restore vision lost to NAION, though research is ongoing.

Can NAION affect both eyes?

Yes. While NAION typically presents in one eye at a time, patients who have had NAION in one eye face an elevated risk of developing it in the other eye, particularly if the underlying risk factors — including ongoing GLP-1 use — persist.

Should I stop taking my GLP-1 medication?

Do not stop any prescribed medication without consulting your doctor. If you are concerned about NAION risk, discuss your specific risk factors with your prescribing physician, who can help you weigh the benefits and risks of continued use.

How strong are NAION legal claims compared to gastroparesis claims?

NAION claims are newer and the body of supporting research is still developing. However, the Harvard study published in a top-tier journal provides significant scientific support. Cases with clear temporal relationship between GLP-1 use and NAION onset, combined with thorough ophthalmologic documentation, can be compelling.

What compensation might be available for NAION injuries?

Permanent vision loss is a severe injury with profound impacts on quality of life, earning capacity, and independence. While specific amounts depend on individual circumstances and the overall litigation trajectory, NAION cases involving significant, documented vision impairment represent serious claims within the GLP-1 litigation.

Take the Next Step

Vision loss is among the most devastating injuries a person can experience. If you or a loved one developed NAION or other sudden vision problems after taking Ozempic, Wegovy, Mounjaro, or another GLP-1 drug, you deserve answers about whether the medication was responsible — and what your legal options are.

If you’ve been affected, request a free case review today.

Advertisement. This content is provided for informational purposes only and does not constitute legal advice. NuLegal | Ashkaan Hassan, Esq. | CA Bar #283629